Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, plcKNSA · Entity 1954 | CHIEF STRATEGY OFFICER | April 07, 2026 | April 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Kiniksa Pharmaceuticals International, plc
Report date April 07, 2026 · Filed April 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Ordinary ShareSEC Table I · non-derivative | Direct | 23,130 |
Ending reported balance
After 2026-04-07 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-04-07 · Exercise / conversion · Acquired 2,726 · Balance 23,976 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Row 2 · 2026-04-07 · Tax withholding · Disposed 846 · Balance 23,130 |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-04-07 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-04-07 · Exercise / conversion · Disposed 2,726 · Balance 0 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F2: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 7, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.
F2: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 7, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 14, 2025 Filed Apr 16, 2025 20:38 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 7,000 | $3.80 | $26,600.00 |
DisclosureSEC source: 0001415889-25-010808 · form4-04162025_080444.xml · nonDerivative · entry 1 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 89,363 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024. Read SEC document |
| April 07, 2025 Filed Apr 9, 2025 20:45 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 2,726 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-010487 · form4-04092025_080449.xml · derivative · entry 3 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,726 Underlying: Class A Ordinary Share · 2,726 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F2 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 7, 2022. F2 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 7, 2022. Read SEC document |
| April 07, 2025 Filed Apr 9, 2025 20:45 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Ordinary Share | 801 | $20.28 | $16,244.28 |
DisclosureSEC source: 0001415889-25-010487 · form4-04092025_080449.xml · nonDerivative · entry 2 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,363 Read SEC document |
| April 07, 2025 Filed Apr 9, 2025 20:45 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 2,726 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-010487 · form4-04092025_080449.xml · nonDerivative · entry 1 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,164 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 21:02 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 1,746 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-009998 · form4-04032025_090432.xml · derivative · entry 9 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,235 Underlying: Class A Ordinary Share · 1,746 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F7 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on the vesting commencement date of April 1, 2024, and each yearly anniversary thereafter. F7 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on the vesting commencement date of April 1, 2024, and each yearly anniversary thereafter. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 21:02 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 1,773 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-009998 · form4-04032025_090432.xml · derivative · entry 8 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,545 Underlying: Class A Ordinary Share · 1,773 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F6 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 1, 2023. F6 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 1, 2023. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 21:02 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantPerformance Share Unit · Derivative | 19,657 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-009998 · form4-04032025_090432.xml · derivative · entry 7 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,657 Underlying: Class A Ordinary Share · 19,657 shares Expires not disclosed F4 · derivative.exercise_price: Each Performance Share Unit (PSU) represents a contingent right to receive a number of Class A Ordinary Shares of the Issuer based upon the achievement of certain pre-established performance criteria, as certified by the Issuer's Compensation Committee. F5 · derivative.exercise_date: Unless earlier forfeited, each PSU vests and converts into not more than 200% of one Class A Ordinary Share of the Issuer no later than January 30, 2028, unless such date falls on a non-business date, in which case the next business date shall apply. F5 · derivative.expiration_date: Unless earlier forfeited, each PSU vests and converts into not more than 200% of one Class A Ordinary Share of the Issuer no later than January 30, 2028, unless such date falls on a non-business date, in which case the next business date shall apply. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 21:02 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Unit · Derivative | 9,828 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-009998 · form4-04032025_090432.xml · derivative · entry 6 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,828 Underlying: Class A Ordinary Share · 9,828 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F3 · derivative.exercise_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 1, 2025. F3 · derivative.expiration_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 1, 2025. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 21:02 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 39,364 | $0.00 Strike: $21.77 | $0.00 |
DisclosureSEC source: 0001415889-25-009998 · form4-04032025_090432.xml · derivative · entry 5 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,364 Underlying: Class A Ordinary Share · 39,364 shares Expires 2035-03-31 F2 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April1, 2025. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 21:02 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Ordinary Share | 513 | $21.77 | $11,168.01 |
DisclosureSEC source: 0001415889-25-009998 · form4-04032025_090432.xml · nonDerivative · entry 4 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,438 Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 21:02 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Ordinary Share | 521 | $21.77 | $11,342.17 |
DisclosureSEC source: 0001415889-25-009998 · form4-04032025_090432.xml · nonDerivative · entry 3 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,951 Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 21:02 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 1,746 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-009998 · form4-04032025_090432.xml · nonDerivative · entry 2 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,472 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 21:02 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 1,773 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-009998 · form4-04032025_090432.xml · nonDerivative · entry 1 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,726 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| March 16, 2025 Filed Mar 19, 2025 21:50 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 1,964 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-008616 · form4-03192025_090333.xml · derivative · entry 3 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Share · 1,964 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F2 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 16, 2021. F2 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 16, 2021. Read SEC document |
| March 16, 2025 Filed Mar 19, 2025 21:50 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Ordinary Share | 577 | $22.61 | $13,045.97 |
DisclosureSEC source: 0001415889-25-008616 · form4-03192025_090333.xml · nonDerivative · entry 2 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,953 Read SEC document |
| March 16, 2025 Filed Mar 19, 2025 21:50 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 1,964 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-008616 · form4-03192025_090333.xml · nonDerivative · entry 1 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,530 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 20:37 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 7,000 | $0.00 Strike: $3.80 | $0.00 |
DisclosureSEC source: 0001415889-25-007814 · form4-03122025_080305.xml · derivative · entry 3 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,049 Underlying: Class A Ordinary Share · 7,000 shares Expires 2027-06-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 20:37 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 12,409 | $21.06 | $261,333.54 |
DisclosureSEC source: 0001415889-25-007814 · form4-03122025_080305.xml · nonDerivative · entry 2 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 76,566 F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $20.72 and $21.555. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 20:37 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 7,000 | $3.80 | $26,600.00 |
DisclosureSEC source: 0001415889-25-007814 · form4-03122025_080305.xml · nonDerivative · entry 1 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 88,975 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024. Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 21:57 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 7,000 | $0.00 Strike: $3.80 | $0.00 |
DisclosureSEC source: 0001415889-25-003748 · form4-02122025_090204.xml · derivative · entry 3 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,049 Underlying: Class A Ordinary Share · 7,000 shares Expires 2027-06-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 21:57 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 14,000 | $19.57 | $273,980.00 |
DisclosureSEC source: 0001415889-25-003748 · form4-02122025_090204.xml · nonDerivative · entry 2 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 81,975 F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $19.395 and $19.87. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 21:57 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 7,000 | $3.80 | $26,600.00 |
DisclosureSEC source: 0001415889-25-003748 · form4-02122025_090204.xml · nonDerivative · entry 1 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 95,975 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024. Read SEC document |
| January 13, 2025 Filed Jan 15, 2025 21:42 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 7,000 | $0.00 Strike: $3.80 | $0.00 |
DisclosureSEC source: 0001415889-25-001496 · form4-01152025_090106.xml · derivative · entry 4 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,049 Underlying: Class A Ordinary Share · 7,000 shares Expires 2027-06-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024. F4 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| January 13, 2025 Filed Jan 15, 2025 21:42 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 1,677 | $19.08 | $31,997.16 |
DisclosureSEC source: 0001415889-25-001496 · form4-01152025_090106.xml · nonDerivative · entry 3 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 88,975 F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024. F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $18.92 and $19.39. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| January 13, 2025 Filed Jan 15, 2025 21:42 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 12,323 | $18.13 | $223,415.99 |
DisclosureSEC source: 0001415889-25-001496 · form4-01152025_090106.xml · nonDerivative · entry 2 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 90,652 F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $17.92 and $18.89. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| January 13, 2025 Filed Jan 15, 2025 21:42 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 7,000 | $3.80 | $26,600.00 |
DisclosureSEC source: 0001415889-25-001496 · form4-01152025_090106.xml · nonDerivative · entry 1 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 102,975 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024. Read SEC document |
| December 16, 2024 Filed Dec 18, 2024 21:45 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 16,017 | $0.00 Strike: $1.59 | $0.00 |
DisclosureSEC source: 0001415889-24-029747 · form4-12182024_091234.xml · derivative · entry 3 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Share · 16,017 shares Expires 2025-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| December 16, 2024 Filed Dec 18, 2024 21:45 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 23,017 | $20.44 | $470,467.48 |
DisclosureSEC source: 0001415889-24-029747 · form4-12182024_091234.xml · nonDerivative · entry 2 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 95,975 F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $20.09 and $20.89. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| December 16, 2024 Filed Dec 18, 2024 21:45 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 16,017 | $1.59 | $25,467.03 |
DisclosureSEC source: 0001415889-24-029747 · form4-12182024_091234.xml · nonDerivative · entry 1 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 118,992 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024. Read SEC document |
| November 18, 2024 Filed Nov 20, 2024 21:39 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 10,000 | $0.00 Strike: $1.59 | $0.00 |
DisclosureSEC source: 0001415889-24-027354 · form4-11202024_091114.xml · derivative · entry 3 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,017 Underlying: Class A Ordinary Share · 10,000 shares Expires 2025-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| November 18, 2024 Filed Nov 20, 2024 21:39 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 17,000 | $21.04 | $357,680.00 |
DisclosureSEC source: 0001415889-24-027354 · form4-11202024_091114.xml · nonDerivative · entry 2 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 102,975 F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $20.685 and $21.505. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| November 18, 2024 Filed Nov 20, 2024 21:39 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 10,000 | $1.59 | $15,900.00 |
DisclosureSEC source: 0001415889-24-027354 · form4-11202024_091114.xml · nonDerivative · entry 1 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 119,975 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024. Read SEC document |
| October 15, 2024 Filed Oct 17, 2024 20:35 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 10,000 | $0.00 Strike: $1.59 | $0.00 |
DisclosureSEC source: 0001415889-24-025374 · form4-10172024_081035.xml · derivative · entry 3 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,017 Underlying: Class A Ordinary Share · 10,000 shares Expires 2025-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| October 15, 2024 Filed Oct 17, 2024 20:35 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 17,000 | $26.87 | $456,790.00 |
DisclosureSEC source: 0001415889-24-025374 · form4-10172024_081035.xml · nonDerivative · entry 2 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 109,975 F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $26.465 and $27.15. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| October 15, 2024 Filed Oct 17, 2024 20:35 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 10,000 | $1.59 | $15,900.00 |
DisclosureSEC source: 0001415889-24-025374 · form4-10172024_081035.xml · nonDerivative · entry 1 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 126,975 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024. Read SEC document |
| September 23, 2024 Filed Sep 25, 2024 20:39 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 10,000 | $0.00 Strike: $1.59 | $0.00 |
DisclosureSEC source: 0001415889-24-023954 · form4-09252024_080916.xml · derivative · entry 3 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,017 Underlying: Class A Ordinary Share · 10,000 shares Expires 2025-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| September 23, 2024 Filed Sep 25, 2024 20:39 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 17,500 | $24.99 | $437,325.00 |
DisclosureSEC source: 0001415889-24-023954 · form4-09252024_080916.xml · nonDerivative · entry 2 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 116,975 F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $24.62 and $25.60. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| September 23, 2024 Filed Sep 25, 2024 20:39 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 10,000 | $1.59 | $15,900.00 |
DisclosureSEC source: 0001415889-24-023954 · form4-09252024_080916.xml · nonDerivative · entry 1 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 134,475 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024. Read SEC document |
| September 02, 2024 Filed Sep 5, 2024 00:53 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 1,964 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-022862 · form4-09052024_120923.xml · derivative · entry 9 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,964 Underlying: Class A Ordinary Share · 1,964 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F6 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the vesting commencement date September 2, 2021. F6 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the vesting commencement date September 2, 2021. Read SEC document |
| September 02, 2024 Filed Sep 5, 2024 00:53 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Ordinary Share | 577 | $26.74 | $15,428.98 |
DisclosureSEC source: 0001415889-24-022862 · form4-09052024_120923.xml · nonDerivative · entry 4 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 124,475 Read SEC document |
| September 02, 2024 Filed Sep 5, 2024 00:53 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 1,964 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-022862 · form4-09052024_120923.xml · nonDerivative · entry 3 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,052 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 01, 2024 Filed Sep 5, 2024 00:53 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 1,773 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-022862 · form4-09052024_120923.xml · derivative · entry 8 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,318 Underlying: Class A Ordinary Share · 1,773 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F5 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023. F5 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023. Read SEC document |
| September 01, 2024 Filed Sep 5, 2024 00:53 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 2,726 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-022862 · form4-09052024_120923.xml · derivative · entry 7 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,452 Underlying: Class A Ordinary Share · 2,726 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F4 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022. F4 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022. Read SEC document |
| September 01, 2024 Filed Sep 5, 2024 00:53 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 36,300 | $0.00 Strike: $26.74 | $0.00 |
DisclosureSEC source: 0001415889-24-022862 · form4-09052024_120923.xml · derivative · entry 6 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,300 Underlying: Class A Ordinary Share · 36,300 shares Expires 2034-08-31 F3 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2024. Read SEC document |
| September 01, 2024 Filed Sep 5, 2024 00:53 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Unit · Derivative | 6,981 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-022862 · form4-09052024_120923.xml · derivative · entry 5 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,981 Underlying: Class A Ordinary Share · 6,981 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F2 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2024. F2 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2024. Read SEC document |
| September 01, 2024 Filed Sep 5, 2024 00:53 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Ordinary Share | 1,322 | $26.74 | $35,350.28 |
DisclosureSEC source: 0001415889-24-022862 · form4-09052024_120923.xml · nonDerivative · entry 2 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,088 Read SEC document |
| September 01, 2024 Filed Sep 5, 2024 00:53 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 4,499 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-022862 · form4-09052024_120923.xml · nonDerivative · entry 1 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 124,410 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| August 27, 2024 Filed Aug 29, 2024 20:36 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 10,000 | $0.00 Strike: $1.59 | $0.00 |
DisclosureSEC source: 0001415889-24-022560 · form4-08292024_080838.xml · derivative · entry 3 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 46,017 Underlying: Class A Ordinary Share · 10,000 shares Expires 2025-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| August 27, 2024 Filed Aug 29, 2024 20:36 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 17,500 | $26.91 | $470,925.00 |
DisclosureSEC source: 0001415889-24-022560 · form4-08292024_080838.xml · nonDerivative · entry 2 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 119,911 F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $26.58 and $27.36. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| August 27, 2024 Filed Aug 29, 2024 20:36 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 10,000 | $1.59 | $15,900.00 |
DisclosureSEC source: 0001415889-24-022560 · form4-08292024_080838.xml · nonDerivative · entry 1 Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 137,411 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.